N-Desmethylnefopam is the main metabolite of Nefopam. N-Desmethylnefopam is a centrally-acting but non-opioid analgesic agent, for the relief of moderate to severe pain. Nefopam targets β-catenin protein level in mesenchymal cells in-vitro and in-vivo. References: [1]. Mittur A. A Simultaneous Mixed-Effects Pharmacokinetic Model for Nefopam, N-desmethylnefopam, and Nefopam N-Oxide in Human Plasma and Urine. Eur J Drug Metab Pharmacokinet. 2018 Aug;43(4):391-404. [2]. Kim KH, et al. Rediscovery of nefopam for the treatment of neuropathic pain. Korean J Pain. 2014 Apr;27(2):103-11. [3]. Baht GS, et al. Pharmacologically targeting beta-catenin for NF1 associated deficiencies in fracture repair. Bone. 2017 May;98:31-36.

纯度：≥98%

CAS：46868-19-3